Moderate riskFDA DrugClass II

Taro Lidocaine Ointment 5% recalled for failed strength specifications

Taro Pharmaceuticals is recalling one lot of Lidocaine Ointment USP 5% because testing found the active ingredient strength was outside acceptable limits. The affected lot was identified during long-term stability testing. No injuries have been reported.

From the FDA notice · Read the official notice ↗ · All Sun Pharmaceutical recalls

What to do

  1. Check if you have lot #AD48154 with expiration date 4/30/2027
  2. Do not use this ointment; contact your pharmacy or healthcare provider for a replacement
  3. Return the product to your pharmacy

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Lidocaine Ointment USP, 5%, Speermint Flavor, 50 g Jar, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, L6T1C, Canada, Dist By: Taro Pharmaceuticals U.S.A. Inc. Hawthorne NY 70532 NDC: 51672-3008-5
Sold in
Nationwide
Made for
All ages (0 months and older)

Details

Units affected
65,328 50g jars
Illnesses reported
None reported
Manufactured in
3 Skyline Dr, N/A, Hawthorne, NY, United States
Classification
Class II
Recall number
D-0848-2026

In the FDA's words

Description
Lidocaine Ointment USP, 5%, Speermint Flavor, 50 g Jar, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, L6T1C, Canada, Dist By: Taro Pharmaceuticals U.S.A. Inc. Hawthorne NY 70532 NDC: 51672-3008-5 Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH). Lot # AD48154, Exp: 4/30/2027. Distribution: Nationwide in the USA Affected quantity: 65,328 50g jars
Hazard
Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).

Related topics

PotencyDrugsSold nationwideMore from FDA Drug